EqualOcean uses cookies to improve functionality and performance of this site. More information could be found in our Privacy Policy. By continuing to browse this site, you consent to the use of cookies.

Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

Healthcare

Filter by: collapse

By Relevance

By Relevance
  • By Asc Time
  • By Desc Time

Company

Company
  • United Imaging Healthcare
  • InferVision
  • 12Sigma
  • VoxelCloud
  • medlinker
  • Deepwise
  • Huiyihuiying
  • Miaoshou.com
  • I-Mab Biopharma
  • Jacobiopharma
  • Yucebio
  • Shcell
  • Medtrum

Author

Author
  • Huang Yuanpu
  • Feng Linyan
  • Zhang Fan
  • Fu Yingwei
  • Zheng ShiYu
  • Tang Shiyu
  • Li Jia
  • Tang Shiyu
  • Xie Xin
  • Qasim Khan
  • Wang Zekun
  • Annie Chen
  • An Feng
  • Yusuf Tuna
  • Sylvia Liang
  • Wang Butao
  • Zhang Jingwen
  • Shang Yang
  • Ivan Platonov
  • Zhou Sirui
  • Zhou Huiting
  • Qiu Yuxian
  • WIM Committee
  • Aysen Sutakov
  • Li Chunhui
  • Yi Huicong
With UBS as Bookrunner, Haohai Biotech Goes Public on Star Market
by Ivan Platonov Oct. 21, 2019
With UBS as Bookrunner, Haohai Biotech Goes Public on Star Market
The firm, which is currently listed in Hong Kong, has priced its Shanghai IPO at CNY 89.23 a share – the highest listing price on the new sci-tech board to date.
by Ivan Platonov Oct. 21, 2019
Healthcare Manufacturing

With UBS as Bookrunner, Haohai Biotech Goes Public on Star Market

by Ivan Platonov Oct. 21, 2019
'The Great Globalization Forward' Continues in CRO Scene: dMed Secures New Round
by Yusuf Tuna Oct. 19, 2019
'The Great Globalization Forward' Continues in CRO Scene: dMed Secures New Round
Qiming-backed dMed Biopharma undertook its Series B funding round worth USD 55 million led by Vivo Capital. The transaction represented yet another funding in China's rising CRO industry stemming from the newly-drafted NMPA policies.
by Yusuf Tuna Oct. 19, 2019
Healthcare

'The Great Globalization Forward' Continues in CRO Scene: dMed Secures New Round

by Yusuf Tuna Oct. 19, 2019
Pinduoduo's Latecomer Online Pharmacy Unit Bets on Medical Devices
by Yusuf Tuna Oct. 7, 2019
Pinduoduo's Latecomer Online Pharmacy Unit Bets on Medical Devices
Pinduoduo, a formidable contender for Alibaba and JD.com in the mainland, has accumulated serious traffic on its 'online pharmacy' unit and cemented its healthcare category by the promotion of affordable medical devices.
by Yusuf Tuna Oct. 7, 2019
Healthcare

Pinduoduo's Latecomer Online Pharmacy Unit Bets on Medical Devices

by Yusuf Tuna Oct. 7, 2019
Chinese Drugmakers Gear Up in R&D to Develop Lucrative Novel Drugs
by Yusuf Tuna Oct. 4, 2019
Chinese Drugmakers Gear Up in R&D to Develop Lucrative Novel Drugs
Since the introduction of new national drug policy, China's largest pharmaceutical companies have been increasing their efforts in R&D to produce ‘Made in China’ novel drugs.
by Yusuf Tuna Oct. 4, 2019
Healthcare

Chinese Drugmakers Gear Up in R&D to Develop Lucrative Novel Drugs

by Yusuf Tuna Oct. 4, 2019
BGI Reinvests in an NGS Services Startup Geneplus
by Yusuf Tuna Oct. 2, 2019
BGI Reinvests in an NGS Services Startup Geneplus
Geneplus has carried out its Series B funding round led by Co-Stone Asset Management and its former investors, including BGI Genomics.
by Yusuf Tuna Oct. 2, 2019
Healthcare

BGI Reinvests in an NGS Services Startup Geneplus

by Yusuf Tuna Oct. 2, 2019
Hotgen Biotech Bursts onto Shanghai Sci-Tech Board, Its Shares Up 140%
by Ivan Platonov Oct. 1, 2019
Hotgen Biotech Bursts onto Shanghai Sci-Tech Board, Its Shares Up 140%
The second biotech firm on the Star Market closed the first day of trading at 91 times earnings.
by Ivan Platonov Oct. 1, 2019
Healthcare Financial

Hotgen Biotech Bursts onto Shanghai Sci-Tech Board, Its Shares Up 140%

by Ivan Platonov Oct. 1, 2019
China's Xiidra Challenger VivaVision Biopharma Carries Out Series C
by Yusuf Tuna Sep. 28, 2019
China's Xiidra Challenger VivaVision Biopharma Carries Out Series C
VivaVision Biopharma undertook its Series C funding round, hoping to create a blockbuster drug for the treatment of ‘dry eye syndrome.’
by Yusuf Tuna Sep. 28, 2019
Healthcare

China's Xiidra Challenger VivaVision Biopharma Carries Out Series C

by Yusuf Tuna Sep. 28, 2019
WIM Salon | Healthcare for 1.4 billion
by WIM Committee Sep. 27, 2019
WIM Salon | Healthcare for 1.4 billion
As China's primary markets experiencing the "capital winter," healthcare industry could maintain its attractiveness in 2019, representing a safe harbour for businesses and investor. We invite you to attend our Salon to understand the cutting-edge trends and the new normal of the healthcare industry.
by WIM Committee Sep. 27, 2019
Healthcare

WIM Salon | Healthcare for 1.4 billion

by WIM Committee Sep. 27, 2019
READ MORE

EqualOcean is a leading industrial tech media and investment research company that focuses on technological and industrial innovation in China.

We aim to assist Chinese entrepreneurial enterprises to break into the global market and provide overseas investors, VCs, and enterprises with a deeper understanding of China's business environment and to seize opportunities in China.

Join over 800,000 of your peers

PRIVACY TERMS OF SERVICE COPYRIGHT

Copyright 2018-2019 EqualOcean.com